Paul Griffin

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

Standard Deviations, Immunology, Pharmacotherapy +19

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance

Patrick N. A. Harris, Paul Anantharajah Tambyah, David Chien Lye et al. · JAMA · 2018 · 731 citations · Full text

Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry To Identify Vancomycin-Resistant Enterococci and Investigate the Epidemiology of an Outbreak

Paul Griffin, Gareth Price, Jacqueline Schooneveldt et al. · Journal of Clinical Microbiology · 2012 · 185 citations · Full text

A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs

James McCarthy, Silvana Sekuloski, Paul Griffin et al. · PLoS ONE · 2011 · 172 citations · Full text